Key result
A 45-year-old female with suspected malignant hyperthermia successfully survived the episode through early detection, active cooling, and aggressive supportive management despite the nonavailability of dantrolene.
Case Report (n=1)
No
Early detection and aggressive supportive management can lead to survival in suspected malignant hyperthermia even when dantrolene is unavailable.
Answers are grounded in this paper and cite their sources.
Suspected MH case adds to sparse Indian reports; leaves open need for diagnostic centers and awareness protocols.
Malignant hyperthermia is rare inherited disorder in our part of the world; there are only few cases reported in literature in India who were suspected of having this condition. The overall incidence of malignant hyperthermia during general anesthesia is estimated to range from 1: 5000 to 1: 50,000–100,000 and mortality rate is estimated to be <5% in the presence of standard care. In India, there is no center where in vitro halothane caffeine contraction test is performed to confirm diagnosis in suspected cases. Second, dantrolene drug of choice for this condition is not freely available in market in India and is stored only in some hospitals in few major cities. Among the cases reported of suspected of malignant hyperthermia in India almost 50% have survived the condition despite nonavailability of dantrolene emphasizing role of early detection and aggressive management in these cases.
No takes yet. Share an insight, caveat, or question.
Iqbal et al. (2017) conducted a case report in Suspected malignant hyperthermia (n=1). Active cooling and supportive management without dantrolene was evaluated on Survival and recovery. A 45-year-old female with suspected malignant hyperthermia successfully survived the episode through early detection, active cooling, and aggressive supportive management despite the nonavailability of dantrolene.
Synapse has enriched 10 related papers. Consider them for comparative context: